Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Wesley W. Day"'
Autor:
Charles H. Bowden, Arthur L. Burnett, John P. Mulhall, Winnie Shih, Judd W. Moul, Run Wang, Wesley W. Day, Kevin T. McVary, Karen DiDonato
Publikováno v:
Journal of Urology. 189:2229-2236
We evaluated the safety and efficacy of 100 and 200 mg avanafil for the treatment of adult males with erectile dysfunction after bilateral nerve sparing radical prostatectomy.This was a double-blind, placebo controlled, parallel group, phase 3 study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2bcf235ce84b66d1060197fda648583
https://doi.org/10.1016/j.juro.2012.11.177
https://doi.org/10.1016/j.juro.2012.11.177
Autor:
Suzanne Oparil, Michael H. Davidson, Charles H. Bowden, Serena Tonstad, Wesley W. Day, Michael Schwiers
Publikováno v:
The American Journal of Cardiology. 111:1131-1138
The aim of this analysis was to evaluate changes in cardiovascular risk factors in obese patients with dyslipidemia and/or hypertension receiving phentermine (PHEN) and topiramate extended-release (TPM ER). In the 56-week, randomized, double-blind, p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00c40987b851f44469792185a63b9b7d
https://doi.org/10.1016/j.amjcard.2012.12.038
https://doi.org/10.1016/j.amjcard.2012.12.038
Autor:
LeRoy Jones, Charles H. Bowden, K. Didonato, Irwin Goldstein, Brenda A. Trask, Laurence H. Belkoff, Wesley W. Day, A. McCullough
Publikováno v:
International Journal of Clinical Practice. 67:333-341
Summary Aim: Determine the long-term efficacy, safety and tolerability of avanafil, a highly specific, rapidly absorbed phosphodiesterase type 5 inhibitor in male patients with mild to severe erectile dysfunction (ED), with or without diabetes. Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::158bf522a6b3f2ec3c71528275fea3a0
https://doi.org/10.1111/ijcp.12065
https://doi.org/10.1111/ijcp.12065
Autor:
Karen DiDonato, Wesley W. Day, Wayne J.G. Hellstrom, Andrew McCullough, Brenda A. Trask, Irwin Goldstein, LeRoy Jones, Charles H. Bowden
Publikováno v:
The Journal of Sexual Medicine. 9:1122-1133
Introduction Phosphodiesterase type 5 (PDE5) inhibitors have become standard treatment for erectile dysfunction (ED). Aim To prospectively evaluate the safety and efficacy of avanafil, a novel PDE5 inhibitor, in men with mild to severe ED. Methods In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::957bcdef92f2225fd69313a17a0f7411
https://doi.org/10.1111/j.1743-6109.2011.02629.x
https://doi.org/10.1111/j.1743-6109.2011.02629.x
Autor:
Kishore M. Gadde, Donna H. Ryan, Michelle Look, Michael Schwiers, David B. Allison, W. Timothy Garvey, Wesley W. Day, Craig A. Peterson, Charles H. Bowden
Publikováno v:
The American Journal of Clinical Nutrition. 95:297-308
Background: Obesity is a serious chronic disease. Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has previously shown significant weight loss compared with placebo in a 56-wk study in overweight and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1657d3bfd250f25fa8e11790969b7c51
https://doi.org/10.3945/ajcn.111.024927
https://doi.org/10.3945/ajcn.111.024927
Autor:
Peter Y. Tam, Craig A. Peterson, Barbara Troupin, Kishore M. Gadde, David B. Allison, Michael Schwiers, William Timothy Garvey, Wesley W. Day, Thomas Najarian
Publikováno v:
Obesity (Silver Spring, Md.)
A 56-week randomized controlled trial was conducted to evaluate safety and efficacy of a controlled-release combination of phentermine and topiramate (PHEN/TPM CR) for weight loss (WL) and metabolic improvements. Men and women with class II and III o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd5a4908628f5458c4cf2a9c4425a657
http://europepmc.org/articles/PMC3270297
http://europepmc.org/articles/PMC3270297
Publikováno v:
Obstetrics & Gynecology. 111:1343-1351
To investigate the safety and efficacy of a transdermal estradiol (E2) spray in women with postmenopausal vasomotor symptoms.A randomized, double-blind, placebo-controlled, multicenter, parallel-group clinical trial was conducted. Postmenopausal wome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d77a369750703d32e1be192989702d27
https://doi.org/10.1097/aog.0b013e318175d162
https://doi.org/10.1097/aog.0b013e318175d162
Publikováno v:
Journal of Hypertension
Weight loss can reduce the increased cardiovascular risk associated with obesity. Pharmacotherapy is a recognized weight loss treatment option; however, cardiovascular safety issues with some previous weight loss drugs raise concerns for newly approv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9929dedae1accae3b6807c89e28fc02
https://pubmed.ncbi.nlm.nih.gov/24621808
https://pubmed.ncbi.nlm.nih.gov/24621808
Autor:
Barbara Troupin, Nancy J. V. Bohannon, W. Timothy Garvey, Donna H. Ryan, Wesley W. Day, Robert R. Henry, Michael Schwiers, Hermann Toplak
Publikováno v:
Diabetes Care
OBJECTIVE To evaluate over 108 weeks the effect of phentermine and topiramate extended release (PHEN/TPM ER) treatment on progression to type 2 diabetes and/or cardiometabolic disease in subjects with prediabetes and/or metabolic syndrome (MetS) at b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfa3422e45d14f9b830442a2ea6f221d
https://pubmed.ncbi.nlm.nih.gov/24103901
https://pubmed.ncbi.nlm.nih.gov/24103901
Publikováno v:
Circulation. 127
Background: Obesity is associated with increased risk of hypertension (HTN). Weight loss can reduce blood pressure (BP) and prevent progression to HTN. In the CONQUER trial, overweight/obese subjects with ≥2 weight-related comorbidities had signifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::327bf23b2f5f7d254349241f64f7c1f7
https://doi.org/10.1161/circ.127.suppl_12.ap027
https://doi.org/10.1161/circ.127.suppl_12.ap027